Pacira | PCRX - Fremdkapital





Fremdkapital Veränderung Datum
Astellas Pharma JPY 320B 0 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Cara Therapeutics USD 0 0 2025-03
Coherus Biosciences USD 51.08M 496K 2025-12
Heron Therapeutics USD 140.64M 975K 2025-12
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
J&J USD 37.34B 183M 2026-06
Ligand Pharmaceuticals USD 446.9M 704K 2026-03
Nektar Therapeutics USD 60.27M 2.89M 2026-03
Novo Nordisk DKK 121.79B 2.62B 2026-06
Omeros USD 403.72M 27.2M 2024-06
Pacira USD 363.12M 4.53M 2026-06
Perrigo USD 3.28B 337.7M 2026-06
Pfizer USD 60.5B 70M 2026-06
Supernus Pharmaceuticals USD 400.38M 21.13M 2022-03
Teva Pharmaceutical Industries USD 12.09B 1.92B 2026-06
Xeris Pharmaceuticals USD 188.81M 32.42M 2026-06
Zoetis USD 9.05B 3M 2026-06